Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a hormone cream ease Post-Radiation vaginal pain? new trial investigates

NCT ID NCT07407647

Symptom relief Sponsor: Ohio State University Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether a vaginal DHEA suppository can safely improve vaginal health in 25 women who had radiation for gynecologic, anal, or rectal cancer. Radiation often causes dryness, burning, and pain, similar to menopause. DHEA is a hormone replacement that may help. The study checks for side effects and changes in the vaginal microbiome.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Prasterone (DHEA) vaginal suppository
What this could lead to
If it works, this could offer a hormone-based option to relieve vaginal discomfort and improve quality of life for women after pelvic radiation.
What could go wrong
This is a small early-phase trial with only 25 participants, so results may not apply to everyone. DHEA can cause side effects like vaginal discharge or irritation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 25 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Any patient with anal, rectal, cervical, vaginal, or vulvar cancer receiving external beam radiation alone, or both external beam radiation and brachytherapy with curative intent (Participants will be consented and enrolled prior to starting treatment but will not receive intervention till after treatment is completed) * Concurrent or prior chemotherapy is allowed * Any prior gynecologic surgery is permitted * Rectal surgery, including lower anterior resection and abdominoperineal resection, is permitted * Subject must be menopausal, which is defined as age \> 50 with no menses for 12 months or bilateral oophorectomy Exclusion Criteria: * Patients with scleroderma, mixed connective tissue disorder, and lupus will be excluded * Patients who have received prior pelvic radiation * Undiagnosed abnormal genital bleeding (unrelated to current diagnosis or treatment related toxicity) * Endometrial cancer or endometrial hyperplasia * Use of estrogen alone injectable or progestin implant therapy with 3 months before study entry * Use of estrogen pellet or progestin injectable drug within 6 months before study entry * Use of oral estrogen, progestin, or DHEA or intrauterine progestin within 8 weeks before study entry * Use of vaginal estrogen (rings, creams, tablets, or gels), transdermal estrogen +/- progestin, vaginal hyaluronic acid, or pro-estrogenic herbal treatments such as black cohosh in the 4 weeks before study entry. Intravaginal moisturizers and lubricants prior to enrollment are permitted * History of breast cancer * Patients receiving palliative radiation therapy * Patients who do not meet criteria for menopause

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anal carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anal carcinoma anus neoplasm cervical carcinoma female reproductive organ cancer rectal carcinoma rectal neoplasm Uterine Cervical Neoplasms vaginal cancer vaginal carcinoma vulva cancer vulvar carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anal carcinoma Cervical carcinoma Malignant female reproductive system neoplasm Rectal carcinoma Vaginal carcinoma Vulvar carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Ohio State University Comprehensive Cancer Center

    RECRUITING

    Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.